OpenNashEarnings

Medical Devices · Nasdaq: DXCM

Dexcom earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 11 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Dexcom published its CONNECT type 2 trial in NEJM, advancing the case for Medicare coverage of non-insulin users, while moving about half its U.S. base to G7 15 Day.

Dexcom says it took share again in the U.S., with its biggest gains among people with type 2 diabetes, including those not on insulin. It launched a redesigned Stelo app and kept rolling out the G7 15 Day sensor, with pump connectivity now broadly available. The CONNECT randomized trial of type 2 patients not on insulin was published in The New England Journal of Medicine after quarter end. Ireland began commercial production on schedule.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history

Revenue$1.3B+11.2% y/yQ3 2026
Q4 2024: $1.1B (worked out from the annual figure)Q4 ’24$1.1BQ1 2025: $1.0BQ1 ’25$1.0BQ2 2025: $1.2BQ2 ’25$1.2BQ3 2025: $1.2BQ3 ’25$1.2BQ4 2025: $1.3B (worked out from the annual figure)Q4 ’25$1.3BQ1 2026: $1.2BQ1 ’26$1.2BQ2 2026: $1.3BQ2 ’26$1.3BQ3 2026: $1.3BQ3 ’26$1.3B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$1.1B *
Q1 2025$1.0B
Q2 2025$1.2B
Q3 2025$1.2B
Q4 2025$1.3B *
Q1 2026$1.2B
Q2 2026$1.3B
Q3 2026$1.3B
Diluted EPS (GAAP)$0.72+2.9% y/yQ3 2026
Q1 2025: $0.27Q1 ’25$0.27Q2 2025: $0.45Q2 ’25$0.45Q3 2025: $0.70Q3 ’25$0.70Q1 2026: $0.51Q1 ’26$0.51Q2 2026: $0.64Q2 ’26$0.64Q3 2026: $0.72Q3 ’26$0.72
Data
Q1 2025$0.27
Q2 2025$0.45
Q3 2025$0.70
Q1 2026$0.51
Q2 2026$0.64
Q3 2026$0.72

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin24.3%+4.2 pts y/yQ3 2026
Q4 2024: 17.0%Q4 ’2417.0%Q1 2025: 12.9%Q1 ’2512.9%Q2 2025: 18.4%Q2 ’2518.4%Q3 2025: 20.1%Q3 ’2520.1%Q4 2025: 25.6%Q4 ’2525.6%Q1 2026: 21.4%Q1 ’2621.4%Q2 2026: 24.3%Q2 ’2624.3%Q3 2026: 24.3%Q3 ’2624.3%
Data
Q4 202417.0%
Q1 202512.9%
Q2 202518.4%
Q3 202520.1%
Q4 202525.6%
Q1 202621.4%
Q2 202624.3%
Q3 202624.3%
Free cash flow$272.7M−52.9% y/yQ3 2026
Q4 2024: $176.8MQ4 ’24$176.8MQ1 2025: $96.8MQ1 ’25$96.8MQ2 2025: $208.9MQ2 ’25$208.9MQ3 2025: $579.4MQ3 ’25$579.4MQ4 2025: $192.1MQ4 ’25$192.1MQ1 2026: $449.0MQ1 ’26$449.0MQ2 2026: $184.5MQ2 ’26$184.5MQ3 2026: $272.7MQ3 ’26$272.7M
Data
Q4 2024$176.8M
Q1 2025$96.8M
Q2 2025$208.9M
Q3 2025$579.4M
Q4 2025$192.1M
Q1 2026$449.0M
Q2 2026$184.5M
Q3 2026$272.7M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$1.1Bd$1.0B$1.2B$1.2B$1.3Bd$1.2B$1.3B$1.3B
Gross margin58.9%56.9%59.5%60.5%62.9%62.9%63.4%64.3%
Operating income$188.9Md$133.7M$212.6M$242.5M$323.0Md$255.3M$318.3M$327.2M
Operating margin17.0%12.9%18.4%20.1%25.6%21.4%24.3%24.3%
Net income$151.7Md$105.4M$179.8M$283.8M$267.3Md$199.5M$249.1M$275.1M
Diluted EPS—$0.27$0.45$0.70—$0.51$0.64$0.72
Operating cash flow$301.4Md$183.8M$303.0Md$659.9Md$294.0Md$525.6M$269.2Md$325.6Md
Capital expenditure$124.6Md$87.0M$94.1Md$80.5Md$101.9Md$76.6M$84.7Md$52.9Md
Free cash flow$176.8M$96.8M$208.9M$579.4M$192.1M$449.0M$184.5M$272.7M
R&D expense$139.5Md$145.2M$148.2M$157.5M$148.2Md$145.3M$153.0M$161.6M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings